The results of investigating the efficacy and safety of non-medical switching from the original rituximab to its biosimilar in rheumatoid arthritis patients (AMBIRA study)

Por M. A. Korolev, Yu. B. Ubshaeva, N. Y. Banshchikova, E. A. Letyagina, A. A. Mullagaliev
Publicado em 2021-01-01